Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07048197
PHASE1/PHASE2

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren's disease

Official title: An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Participants With Difficult-to-treat Rheumatoid Arthritis and Severe, Refractory Sjogren's Disease With Organ Involvement

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

27

Start Date

2025-06-20

Completion Date

2028-11-01

Last Updated

2026-03-30

Healthy Volunteers

No

Interventions

BIOLOGICAL

Rapcabtagene autoleucel

Single infusion of Rapcabtagene autoleucel

Locations (11)

Novartis Investigative Site

Bordeaux, France

Novartis Investigative Site

Brest, France

Novartis Investigative Site

Le Kremlin-Bicêtre, France

Novartis Investigative Site

Lille, France

Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Novartis Investigative Site

Cologne, North Rhine-Westphalia, Germany

Novartis Investigative Site

Berlin, Germany

Novartis Investigative Site

Ulm, Germany

Novartis Investigative Site

Singapore, Singapore

Novartis Investigative Site

Barcelona, Spain

Novartis Investigative Site

Madrid, Spain